Skip to content

Urmila Bajpai, M.D.

NPI 1790932457ActiveIndividual· Internal Medicine, Rheumatology· San Francisco, CA

Internal Medicine, Rheumatology (M.D.) in San Francisco, California, licensed in CA, with an NPI issued in August 2008. Part D covered 751 prescriptions written in 2024, 61% of them generic. Amgen Inc. was the largest of 2 companies reporting payments in 2025, $203.67 in all, mostly food and beverage.

Overview

NPI1790932457
StatusActive
Entity typeIndividual
CredentialM.D.
Sole proprietorNo
NPI issuedAug 25, 2008
Last updated in NPPESAug 25, 2008

Specialties and licenses

TaxonomyCodeLicenseState
Internal Medicine, Rheumatology Primary207RR0500XA100242CA

About license numbers in NPPES

Exclusion screening

ListResultDetails
HHS-OIG LEIE · Oct 9, 2026No matchChecked by NPI and by name + state
North Carolina Medicaid · Nov 10, 2026No match—
New York OMIG · Nov 10, 2026No match—
Ohio Medicaid · Nov 10, 2026No match—
Pennsylvania Medicheck · Nov 10, 2026No match—
Washington HCA · Nov 10, 2026No match—

Official OIG search · How matching works ·Bulk check a roster

Medicare

Enrollment (PECOS)Enrolled Practitioner - Rheumatology (CA)

Part D prescriptions in 2024

Prescriptions (claims)751 · 1,503 30-day fills
Patients129
Total drug cost$2,101,601
Generic share61% of claims

Medicare sources and data years

Industry payments (Open Payments)

  • 2025$203.67 · 2 payments from 2 companies

Top paying companies in 2025

CompanyAmountPayments
Amgen Inc.$125.681
Janssen Biotech, Inc.$77.991

What the 2025 payments were for

  • Food and Beverage$125.68 · 1 payment
  • Education$77.99 · 1 payment

Receiving payments does not imply wrongdoing. What Open Payments covers ·original records

Other Internal Medicine, Rheumatology providers in San Francisco

All Internal Medicine, Rheumatology providers in California →